医药导报2025，Vol.44Issue(6)：955-960,6.DOI:10.3870/j.issn.1004-0781.2025.06.019
氘可来昔替尼治疗中重度斑块状银屑病的成本-效果分析
Cost-Effectiveness Analysis of Deucravacitinib in the Treatment of Moderate to Severe Plaque Psoriasis
摘要
Abstract
Objective To evaluate the cost-effectiveness of deucravacitinib in the treatment of moderate to severe plaque psoriasis from the perspective of the Chinese health system.Methods Based on POETYK PSO-1 study and related cost and utility data,a decision tree combined with Markov model was established.The model period was 10 years,and the output indicators of the model were cost and quality-adjusted life year(QALY).The evaluation index of the model was the incremental cost-effectiveness ratio(ICER).The willingness-to-pay threshold(WTP)was 3 times of China's per capita GDP in 2023.Sensitivity analysis was performed to evaluate the robustness of the model results.Results The incremental utility and incremental cost were 0.598QALYs and 130 677.51 yuan(RMB),respectively.The ICER of the two strategies was 218 487.11 yuan(RMB)per QALY gained,which was less than 3 times GDP per capita in 2023.Sensitivity analyses confirmed the robustness of the model.Conclusion Under the threshold of 3 times the GDP per capita in China,deucravacitinib is cost-effective in the treatment of moderate to severe plaque psoriasis.关键词
氘可来昔替尼/银屑病/药物经济学/卫生技术评估Key words
Deucravacitinib/Psoriasis/Pharmacoeconomics/Health technologyassessment分类
医药卫生引用本文复制引用
冯冰,高宁,高胜男,张冉冉,张羽曦,刘国强..氘可来昔替尼治疗中重度斑块状银屑病的成本-效果分析[J].医药导报,2025,44(6):955-960,6.基金项目
河北省自然科学基金资助项目(H2021206407). （H2021206407）
